{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:13Z","timestamp":1793397913672,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["1028543"],"award-info":[{"award-number":["1028543"]}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","award":["100411"],"award-info":[{"award-number":["100411"]}],"id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies for smoking cessation, but data about their safety in pregnancy are limited. We assessed the risk of adverse perinatal outcomes and major congenital anomalies associated with the use of these therapies in pregnancy in Australia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Perinatal data for 1,017,731 deliveries (2004 to 2012) in New South Wales and Western Australia were linked to pharmaceutical dispensing, hospital admission and death records. We identified 97,875 women who smoked during pregnancy; of those, 233, 330 and 1057 were exposed to bupropion, NRT and varenicline in pregnancy, respectively. Propensity scores were used to match exposed women to those who were unexposed to any smoking therapy (1:10 ratio). Propensity scores and gestational age at exposure were used to match varenicline-exposed to NRT-exposed women (1:1 ratio). Time-dependent Cox proportional hazards models estimated hazard ratios (HR) with 95% confidence intervals (95% CI) for any adverse perinatal event (a composite of 10 unfavourable maternal and neonatal outcomes) and any major congenital anomaly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The risk of any adverse perinatal event was not significantly different between bupropion-exposed and unexposed women (39.2% versus 39.3%, HR 0.93, 95% CI 0.73\u20131.19) and between NRT-exposed and unexposed women (44.8% vs 46.3%, HR 1.02, 95% CI 0.84\u20131.23), but it was significantly lower in women exposed to varenicline (36.9% vs 40.1%, HR 0.86, 95% CI 0.77\u20130.97). Varenicline-exposed infants were less likely than unexposed infants to be born premature (6.5% vs 8.9%, HR 0.72, 95% CI 0.56\u20130.92), be small for gestational age (11.4% vs 15.4%, HR 0.68, 95% CI 0.56\u20130.83) and have severe neonatal complications (6.6% vs 8.2%, HR 0.74, 95% CI 0.57\u20130.96). Among infants exposed to varenicline in the first trimester, 2.9% had a major congenital anomaly (3.5% in unexposed infants, HR 0.91, 95% CI 0.72\u20131.15). Varenicline-exposed women were less likely than NRT-exposed women to have an adverse perinatal event (38.7% vs 51.4%, HR 0.58, 95% CI 0.33\u20131.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pregnancy exposure to smoking cessation pharmacotherapies does not appear to be associated with an increased risk of adverse birth outcomes. Lower risk of adverse birth outcomes in varenicline-exposed pregnancies is inconsistent with recommendations that NRT be used in preference to varenicline.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-019-1472-9","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T02:02:47Z","timestamp":1580868167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-9462","authenticated-orcid":false,"given":"Duong Thuy","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Preen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristjana","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kemp-Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa R.","family":"Jorm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K. Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alys","family":"Havard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"crossref","unstructured":"Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2015;12.","DOI":"10.1002\/14651858.CD010078.pub2"},{"key":"1472_CR2","volume-title":"Supporting smoking cessation: a guide for health professionals","author":"The Royal Australian College of General Practitioners","year":"2014","unstructured":"The Royal Australian College of General Practitioners. Supporting smoking cessation: a guide for health professionals. Melbourne: The Royal Australian College of General Practitioners; 2014."},{"issue":"1","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1465-3362.2009.00098.x","volume":"29","author":"S Schneider","year":"2010","unstructured":"Schneider S, Huy C, Schutz J, Diehl K. Smoking cessation during pregnancy: a systematic literature review. Drug Alcohol Rev. 2010;29(1):81\u201390.","journal-title":"Drug Alcohol Rev"},{"issue":"13","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/1471-0528.12769","volume":"121","author":"DT Tran","year":"2014","unstructured":"Tran D, Roberts C, Jorm L, Seeho S, Havard A. Change in smoking status during two consecutive pregnancies: a population-based cohort study. BJOG. 2014;121(13):1611\u201320.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"issue":"5","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/FTD.0b013e31826ab6c5","volume":"34","author":"G Koren","year":"2012","unstructured":"Koren G. Nicotine-replacement therapy in pregnancy-the end of the road? Ther Drug Monit. 2012;34(5):487\u20138.","journal-title":"Ther Drug Monit"},{"issue":"18","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1001\/jama.2016.2535","volume":"315","author":"A Haddad","year":"2016","unstructured":"Haddad A, Davis AM. Tobacco smoking cessation in adults and pregnant women: behavioral and pharmacotherapy interventions. JAMA. 2016;315(18):2011\u20132.","journal-title":"JAMA."},{"key":"1472_CR7","first-page":"CD009329","volume":"5","author":"K Cahill","year":"2013","unstructured":"Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ntr\/nty055","volume":"21","author":"E Turner","year":"2019","unstructured":"Turner E, Jones M, Vaz LR, Coleman T. Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. Nicotine Tob Res. 2019;21(8):1001\u201310.","journal-title":"Nicotine Tob Res"},{"issue":"\\","key":"1472_CR9","first-page":"e200","volume":"130","author":"The American College of Obstetricians and Gynecologists","year":"2017","unstructured":"The American College of Obstetricians and Gynecologists. Committee opinion no. 721: smoking cessation during pregnancy. Obstet Gynecol. 2017;130(\\):e200.","journal-title":"Obstet Gynecol"},{"key":"1472_CR10","volume-title":"WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. Geneva: World Health Organization; 2013."},{"key":"1472_CR11","first-page":"263981","volume":"2014","author":"YC Kaplan","year":"2014","unstructured":"Kaplan YC, Olgac D\u00fcndar N, Kasap B, Karadas B. Pregnancy outcome after varenicline exposure in the first trimester. Case Rep Obstet Gynecol. 2014;2014:263981.","journal-title":"Case Rep Obstet Gynecol"},{"issue":"10","key":"1472_CR12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.3489","volume":"22","author":"M Harrison-Woolrych","year":"2013","unstructured":"Harrison-Woolrych M, Paterson H, Tan M. Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol Drug Saf. 2013;22(10):1086\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.reprotox.2016.11.010","volume":"67","author":"JL Richardson","year":"2017","unstructured":"Richardson JL, Stephens S, Yates LM, Diav-Citrin O, Arnon J, Beghin D, et al. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 2017;67:26\u201334.","journal-title":"Reprod Toxicol"},{"issue":"4","key":"1472_CR14","first-page":"351","volume":"32","author":"AL Stotts","year":"2015","unstructured":"Stotts AL, Northrup TF, Cinciripini PM, Minnix JA, Blalock JA, Mullen PD, et al. Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions. Am J Perinatol. 2015;32(4):351\u20136.","journal-title":"Am J Perinatol"},{"issue":"4","key":"1472_CR15","doi-asserted-by":"publisher","first-page":"420.e1","DOI":"10.1016\/j.ajog.2016.11.1036","volume":"216","author":"TN Nanovskaya","year":"2017","unstructured":"Nanovskaya TN, Oncken C, Fokina VM, Feinn RS, Clark SM, West H, et al. Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. Am J Obstet Gynecol. 2017;216(4):420.e1\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ajog.2004.09.027","volume":"192","author":"B Chun-Fai-Chan","year":"2005","unstructured":"Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192(3):932\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1472_CR17","doi-asserted-by":"publisher","first-page":"611.e1","DOI":"10.1016\/j.ajog.2016.06.059","volume":"215","author":"A B\u00e9rard","year":"2016","unstructured":"B\u00e9rard A, Zhao J-P, Sheehy O. Success of smoking cessation interventions during pregnancy. Am J Obstet Gynecol. 2016;215(5):611.e1\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"1472_CR18","doi-asserted-by":"publisher","first-page":"g1622","DOI":"10.1136\/bmj.g1622","volume":"348","author":"I Berlin","year":"2014","unstructured":"Berlin I, Grang\u00e9 G, Jacob N, Tanguy M-L. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ. 2014;348:g1622.","journal-title":"BMJ."},{"issue":"3","key":"1472_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-3016.2010.01104.x","volume":"24","author":"TH Lassen","year":"2010","unstructured":"Lassen TH, Madsen M, Skovgaard LT, Strandberg-Larsen K, Olsen J, Andersen AM. Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort. Paediatr Perinat Epidemiol. 2010;24(3):272\u201381.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"11","key":"1472_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1471-0528.2008.01867.x","volume":"115","author":"K Strandberg-Larsen","year":"2008","unstructured":"Strandberg-Larsen K, Tinggaard M, Nybo Andersen AM, Olsen J, Gronbaek M. Use of nicotine replacement therapy during pregnancy and stillbirth: a cohort study. BJOG. 2008;115(11):1405\u201310.","journal-title":"BJOG."},{"issue":"4","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10995-008-0361-1","volume":"13","author":"KH Gaither","year":"2009","unstructured":"Gaither KH, Brunner Huber LR, Thompson ME, Huet-Hudson YM. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern Child Health J. 2009;13(4):497\u2013504.","journal-title":"Matern Child Health J"},{"issue":"9","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"e003692","DOI":"10.1136\/bmjopen-2013-003692","volume":"3","author":"Alys Havard","year":"2013","unstructured":"Havard A, Jorm LR, Preen D, Daube M, Kemp A, Einarsd\u00f3ttir K, et al. The Smoking MUMS (Maternal Use of Medications and Safety) Study: protocol for a population-based cohort study using linked administrative data. BMJ Open. 2013;3(9).","journal-title":"BMJ Open"},{"issue":"8","key":"1472_CR23","doi-asserted-by":"publisher","first-page":"e0202999","DOI":"10.1371\/journal.pone.0202999","volume":"13","author":"L Roper","year":"2018","unstructured":"Roper L, Tran DT, Einarsd\u00f3ttir K, Preen DB, Havard A. Algorithm for resolving discrepancies between claims for smoking cessation pharmacotherapies during pregnancy and smoking status in delivery records: the impact on estimates of utilisation. PLoS One. 2018;13(8):e0202999.","journal-title":"PLoS One"},{"issue":"1","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12874-017-0385-6","volume":"17","author":"DT Tran","year":"2017","unstructured":"Tran DT, Havard A, Jorm LR. Data cleaning and management protocols for linked perinatal research data: a good practice example from the Smoking MUMS (Maternal Use of Medications and Safety) Study. BMC Med Res Methodol. 2017;17(1):97.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/1753-6405.12213","volume":"38","author":"DT Tran","year":"2014","unstructured":"Tran DT, Roberts CL, Havard A, Jorm LR. Linking birth records to hospital admission records enhances the identification of women who smoke during pregnancy. Aust N Z J Public Health. 2014;38(3):258\u201364.","journal-title":"Aust N Z J Public Health"},{"key":"1472_CR26","volume-title":"The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular list of diseases and Alphabetic index of diseases","author":"National Centre for Classification in Health","year":"2008","unstructured":"National Centre for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular list of diseases and Alphabetic index of diseases. Sydney: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2008."},{"key":"1472_CR27","volume-title":"Maternity and Child Health Unit - Strategic Development Division","author":"New South Wales Department of Health. Maternity - Towards Normal Birth in NSW","year":"2010","unstructured":"New South Wales Department of Health. Maternity - Towards Normal Birth in NSW. Maternity and Child Health Unit - Strategic Development Division 2010."},{"key":"1472_CR28","volume-title":"Western Australia\u2019s mothers and babies, 2012: 30th annual report of the Western Australian midwives notification system","author":"M Hutchinson","year":"2015","unstructured":"Hutchinson M. Western Australia\u2019s mothers and babies, 2012: 30th annual report of the Western Australian midwives notification system; 2015."},{"key":"1472_CR29","volume-title":"ATC alterations from 2005-2019","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2019","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC alterations from 2005-2019. Geneva: World Health Organization; 2019. https:\/\/www.whocc.no\/atc_ddd_alterations__cumulative\/atc_alterations\/?order_by=1. Accessed 7 July 2019"},{"issue":"5","key":"1472_CR30","first-page":"291","volume":"197","author":"TA Dobbins","year":"2012","unstructured":"Dobbins TA, Sullivan EA, Roberts CL, Simpson JM. Australian national birthweight percentiles by sex and gestational age, 1998-2007. MJA. 2012;197(5):291\u20134.","journal-title":"MJA."},{"issue":"3","key":"1472_CR31","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s10995-011-0797-6","volume":"16","author":"SJ Lain","year":"2012","unstructured":"Lain SJ, Algert CS, Nassar N, Bowen JR, Roberts CL. Incidence of severe adverse neonatal outcomes: use of a composite indicator in a population cohort. Matern Child Health J. 2012;16(3):600\u20138.","journal-title":"Matern Child Health J"},{"issue":"8","key":"1472_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/MLR.0b013e318178eae4","volume":"46","author":"CL Roberts","year":"2008","unstructured":"Roberts CL, Cameron CA, Bell JC, Algert CS, Morris JM. Measuring maternal morbidity in routinely collected health data: development and validation of a maternal morbidity outcome indicator. Med Care. 2008;46(8):786\u201394.","journal-title":"Med Care"},{"issue":"15","key":"1472_CR33","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1001\/jama.295.15.1809","volume":"295","author":"A Conde-Agudelo","year":"2006","unstructured":"Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA. 2006;295(15):1809\u201323.","journal-title":"JAMA."},{"issue":"21","key":"1472_CR34","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1080\/14767058.2016.1260115","volume":"30","author":"S Appareddy","year":"2017","unstructured":"Appareddy S, Pryor J, Bailey B. Inter-pregnancy interval and adverse outcomes: evidence for an additional risk in health disparate populations. J Matern Fetal Neonatal Med. 2017;30(21):2640\u20134.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1472_CR35","volume-title":"Reporting adverse events: Australian Department of Health","author":"Australian Therapeutic Goods Administration","year":"2018","unstructured":"Australian Therapeutic Goods Administration. Reporting adverse events: Australian Department of Health; 2018. https:\/\/www.tga.gov.au\/reporting-adverse-events#faq. Accessed 25 Oct 2019."},{"key":"1472_CR36","unstructured":"Australian Bureau of Statistics 2033.0.55.001. Census of population and housing: socio-economic indexes for areas (SEIFA), Australia 2006: Australian Bureau of Statistics; 2008. http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/Lookup\/2033.0.55.001Main+Features12006?OpenDocument. Accessed 5 Feb 2018."},{"key":"1472_CR37","unstructured":"Australian Bureau of Statistics. Australian Standard Geographic Classification Remoteness Structure: Commonwealth of Australia; 2010. http:\/\/www.abs.gov.au\/websitedbs\/D3310114.nsf\/home\/remoteness+structure. Accessed 15 Apr 2019."},{"key":"1472_CR38","volume-title":"Performing a 1:N case-control match on propensity sore. Proceedings of the Twenty -Sixth Annual SAS Users Group International Conference","author":"LS Parsons","year":"2004","unstructured":"Parsons LS. Performing a 1:N case-control match on propensity sore. Proceedings of the Twenty -Sixth Annual SAS Users Group International Conference; 2004."},{"issue":"1","key":"1472_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","volume":"17","author":"T-L Nguyen","year":"2017","unstructured":"Nguyen T-L, Collins GS, Spence J, Daur\u00e8s J-P, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17(1):78.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1472_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/add.12633","volume":"109","author":"J Hartmann-Boyce","year":"2014","unstructured":"Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414\u201325.","journal-title":"Addiction."},{"key":"1472_CR41","doi-asserted-by":"publisher","first-page":"b1081","DOI":"10.1136\/bmj.b1081","volume":"338","author":"LME McCowan","year":"2009","unstructured":"McCowan LME, Dekker GA, Chan E, Stewart A, Chappell LC, Hunter M, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. BMJ. 2009;338:b1081.","journal-title":"BMJ."},{"issue":"4","key":"1472_CR42","doi-asserted-by":"publisher","first-page":"e192514","DOI":"10.1001\/jamanetworkopen.2019.2514","volume":"2","author":"S Soneji","year":"2019","unstructured":"Soneji S, Beltr\u00e1n-S\u00e1nchez H. Association of maternal cigarette smoking and smoking cessation with preterm birth. JAMA Netw Open. 2019;2(4):e192514\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1472_CR43","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/AOG.0000000000000679","volume":"125","author":"K Blatt","year":"2015","unstructured":"Blatt K, Moore E, Chen A, Van Hook J, DeFranco EA. Association of reported trimester-specific smoking cessation with fetal growth restriction. Obstet Gynecol. 2015;125(6):1452\u20139.","journal-title":"Obstet Gynecol"},{"key":"1472_CR44","volume-title":"Quality and coverage of the NSW Register of Congenital Conditions using Admitted Patient Data: a record linkage study","author":"Centre for Epidemiology and Evidence","year":"2016","unstructured":"Centre for Epidemiology and Evidence. Quality and coverage of the NSW Register of Congenital Conditions using Admitted Patient Data: a record linkage study. Sydney: NSW Ministry of Health; 2016. https:\/\/www.health.nsw.gov.au\/hsnsw\/Pages\/rocc-apd-linkage-study.aspx. Accessed 4 Apr 2018"},{"issue":"1","key":"1472_CR45","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1472_CR46","volume-title":"EUROCAT prevalence data tables. Cases and prevalence (per 10,000 births) of all congenital anomaly subgroups for all registries, from 2012\u20132016","author":"European Surveillance of Congenital Anomalies","year":"2018","unstructured":"European Surveillance of Congenital Anomalies. EUROCAT prevalence data tables. Cases and prevalence (per 10,000 births) of all congenital anomaly subgroups for all registries, from 2012\u20132016 2018. http:\/\/www.eurocat-network.eu\/accessprevalencedata\/prevalencetables. Accessed 9 Apr 2019."},{"key":"1472_CR47","volume-title":"Chantix (full prescribing information)","author":"Pfizer Laboratories","year":"2019","unstructured":"Pfizer Laboratories. Chantix (full prescribing information) 2019. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=557. Accessed 2 Apr 2019."},{"issue":"10","key":"1472_CR48","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/bdr2.1212","volume":"110","author":"AR Scialli","year":"2018","unstructured":"Scialli AR, Daston G, Chen C, Coder PS, Euling SY, Foreman J, et al. Rethinking developmental toxicity testing: evolution or revolution? Birth Defects Res. 2018;110(10):840\u201350.","journal-title":"Birth Defects Res"},{"issue":"3","key":"1472_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1258\/jrsm.2008.08k033","volume":"102","author":"MB Bracken","year":"2009","unstructured":"Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med. 2009;102(3):120\u20132.","journal-title":"J R Soc Med"},{"key":"1472_CR50","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.drugalcdep.2016.08.184","volume":"171","author":"VM Fokina","year":"2017","unstructured":"Fokina VM, West H, Oncken C, Clark S, Ahmed MS, Hankins G, et al. Bupropion therapy during pregnancy: concentrations of the drug and its major metabolites in umbilical cord plasma and amniotic fluid. Drug Alcohol Depend. 2017;171:e63.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1472_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/npp.2014.147","volume":"40","author":"EJ Ross","year":"2015","unstructured":"Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology. 2015;40(1):61\u201387.","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"1472_CR52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1124\/jpet.301.2.594","volume":"301","author":"D Dempsey","year":"2002","unstructured":"Dempsey D, Jacob P, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002;301(2):594.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1472_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40471-017-0131-y","volume":"4","author":"JW Jackson","year":"2017","unstructured":"Jackson JW, Schmid I, Stuart EA. Propensity scores in pharmacoepidemiology: beyond the horizon. Curr Epidemiol Rep. 2017;4(4):271\u201380.","journal-title":"Curr Epidemiol Rep"},{"issue":"4","key":"1472_CR54","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"key":"1472_CR55","volume-title":"Validation study NSW midwives data collection 1998","author":"L Taylor","year":"2000","unstructured":"Taylor L, Pym M, Bajuk B, Sutton L, Travis S, Banks C. Validation study NSW midwives data collection 1998. Sydney: NSW Health Department; 2000."},{"key":"1472_CR56","unstructured":"Downey F. Validation study of the Western Australian midwives notification system. 2005 data. Department of Health, Western Australia: Perth; 2007."},{"key":"1472_CR57","volume-title":"FDA drug safety communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings 2016. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking. Accessed 25 Oct 2019."},{"issue":"10","key":"1472_CR58","first-page":"S63","volume":"202","author":"ME Davey","year":"2015","unstructured":"Davey ME, Hunt JM, Foster R, Couzos S, van der Sterren AE, Sarin J, et al. Tobacco control policies and activities in aboriginal community-controlled health services. Med J Aust. 2015;202(10):S63\u20136.","journal-title":"Med J Aust"},{"key":"1472_CR59","volume-title":"9.1 socio-economic position and disparities in tobacco exposure and use. In: Scollo MM, Winstanley MH, editors. Tobacco in Australia: facts and issues","author":"EM Greenhalgh","year":"2018","unstructured":"Greenhalgh EM, Scollo MM, Pearce M. 9.1 socio-economic position and disparities in tobacco exposure and use. In: Scollo MM, Winstanley MH, editors. Tobacco in Australia: facts and issues. Melbourne: Cancer Council Victoria; 2018."},{"key":"1472_CR60","unstructured":"Cancer Council New South Wales. NRT factsheet 2016. https:\/\/www.cancercouncil.com.au\/wp-content\/uploads\/2016\/09\/16138_CA_CAN5084_NRTFactsheet_WEB.pdf. Accessed 25 Oct 2019."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-019-1472-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:11:30Z","timestamp":1612397490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-019-1472-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1186\/s12916-019-1472-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project was approved by the Australian Institute of Health and Welfare Ethics Committee, the NSW Population and Health Services Research Ethics Committee, the Department of Health WA Human Research Ethics Committee, the Aboriginal Health and Medical Research Council of NSW Ethics Committee and the Western Australian Aboriginal Health Ethics Committee. The study used routinely collected data that have been anonymised. Waiver of consent to participate was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}